Skip to main content
Premium Trial:

Request an Annual Quote

Sigma-Aldrich, Oxford BioMedica Sue Open Biosystems for RNAi Patent Infringement

NEW YORK, June 14 (GenomeWeb News) - Sigma-Aldrich and Oxford BioMedica have sued Open Biosystems for allegedly infringing two patents that cover lentiviral-based systems for the delivery of foreign DNA into mammalian cells.
The complaint, filed in US District Court Eastern District of Missouri, alleges that Open Biosystems is infringing US Patent Nos. 6,924,123 and 7,056,699.  
Oxford BioMedica received the rights to the '123 patent in August 2005. It received the rights to the '699 patent last week, according to the US Patent and Trade Organization's database. Both patents are entitled "Lentiviral LTR Deleted Vector" and Oxford BioMedica exclusively licensed them to Sigma-Aldrich for research use in October 2005, the companies said.
Their suit claims that Open Biosystems' Lentiviral shRNAmir Library is being sold for "incorporation into viral particles that infringe one or more claims of the patents."  
Shaf Yousaf, president of Sigma-Aldrich's research biotechnology business unit, said in a statement that the company has made "significant investments in creating the most comprehensive portfolio of intellectual property to allow [its] customers freedom to operate in the cutting-edge arena of RNA Interference" and its "actions will be to defend [its] investments and the valuable intellectual property."
Open Biosystems has not issued a statement.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.